James M Wright
James M Wright
Professor of Anesthesiology, Pharmacology & Therapeutics, University of BC
Verified email at ti.ubc.ca - Homepage
Cited by
Cited by
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled …
R Boussageon, T Bejan-Angoulvant, M Saadatian-Elahi, S Lafont, ...
Bmj 343, 2011
First‐line drugs for hypertension
JM Wright, VM Musini, R Gill
Cochrane Database of systematic reviews, 2018
Treatment blood pressure targets for hypertension
JA Arguedas, MI Perez, JM Wright
Cochrane database of systematic reviews, 2009
Pharmacotherapy for mild hypertension
D Diao, JM Wright, DK Cundiff, F Gueyffier
The Cochrane Library, 2012
Should people at low risk of cardiovascular disease take a statin?
JD Abramson, HG Rosenberg, N Jewell, JM Wright
Bmj 347, 2013
Pharmacotherapy for hypertension in the elderly
VM Musini, AM Tejani, K Bassett, JM Wright
Cochrane Database of Systematic Reviews, 2009
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
RJ Ferguson, SMF De Morais, S Benhamou, C Bouchardy, J Blaisdell, ...
Journal of Pharmacology and Experimental Therapeutics 284 (1), 356-361, 1998
Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children
RL Morrow, EJ Garland, JM Wright, M Maclure, S Taylor, CR Dormuth
Cmaj 184 (7), 755-762, 2012
Statin adherence and risk of accidents: a cautionary tale
CR Dormuth, AR Patrick, WH Shrank, JM Wright, RJ Glynn, J Sutherland, ...
Circulation 119 (15), 2051-2057, 2009
Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials
T Bejan-Angoulvant, M Saadatian-Elahi, JM Wright, EB Schron, ...
Journal of hypertension 28 (7), 1366-1372, 2010
Are lipid-lowering guidelines evidence
J Abramson, JM Wright
The Fats of Life 369 (9557), 168-169, 2007
Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?
JM Wright, CH Lee, GK Chambers
Cmaj 161 (1), 25-32, 1999
The double-edged sword of COX-2 selective NSAIDs
JM Wright
Cmaj 167 (10), 1131-1137, 2002
Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine by four different antioxidants in the mouse
TL Perry, VW Yong, RM Clavier, K Jones, JM Wright, JG Foulks, RA Wall
Neuroscience letters 60 (2), 109-114, 1985
Reporting of 6-month vs 12-month data in a clinical trial of celecoxib
JB Hrachovec, M Mora, JM Wright, TL Perry, K Bassett, K Chambers
JAMA 286 (19), 2398-2400, 2001
Blood pressure targets for hypertension in people with diabetes mellitus
JA Arguedas, V Leiva, JM Wright
Cochrane Database of Systematic Reviews, 2013
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension
BS Heran, MMY Wong, IK Heran, JM Wright
Cochrane Database of Systematic Reviews, 2008
Inhibition and induction of cytochrome P4502E1‐catalyzed oxidation by isoniazid in humans
R Zand, SD Nelson, JT Slattery, KE Thummel, TF Kalhorn, SP Adams, ...
Clinical Pharmacology & Therapeutics 54 (2), 142-149, 1993
Thiazolidinediones and fractures in men and women
CR Dormuth, G Carney, B Carleton, K Bassett, JM Wright
Archives of internal medicine 169 (15), 1395-1402, 2009
A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine.
Y Lacourcière, J Lenis, R Orchard, R Lewanczuk, M Houde, Y Pesant, ...
Blood pressure monitoring 3 (5), 295-302, 1998
The system can't perform the operation now. Try again later.
Articles 1–20